Clinical trials: Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
This study is being offered to patients who are post-menopausal, have breast cancer with a positive estrogen and/or progesterone hormone receptor test and are currently awaiting surgery for breast cancer.
- Trial name
- NCT01814865
- Testing
- Abiraterone Acetate, Prednisone, Aromatase Inhibitor
- Where
- 4 sites in Canada
- Sponsor
- British Columbia Cancer Agency